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Abstract
Background: Many misperceptions of both risks and opportunities of e-cigarettes (e-cigs) exist among the general
population and among physicians, although e-cigs could be a valuable harm reduction tool for current smokers.
Methods: Two groups in Flanders, namely general practitioners (GPs; family doctors) and tobacco counselors filled
out an online questionnaire with regard to their attitudes and risk perceptions concerning e-cigs. Statements included
were on the safety and the addictive properties of e-cigs in absolute terms, whereas other items compared e-cigs with
regular tobacco cigarettes. Statements about possible “gateway” and “renormalization” effects, selling to minors, and
use in public places and on the potential of e-cigs as a smoking cessation aid were also included. Respondents were
also asked for the rate at which their patients asked information about e-cigs, if they would recommend e-cigs to their
smoking patients, and whether they had information brochures on e-cigs.
Results: About 70 % believed that e-cigs are harmful to vapers, and about half to two thirds believed that e-cigs are
carcinogenic, increase cardiovascular risk, and increase the risk of chronic lung disease. Also, a substantial minority
incorrectly believed these risks to be no less than those resulting from regular smoking. Ten to almost 20 % disagreed
that e-cigs are healthier and represent less risk for the main serious smoking-related diseases than conventional
cigarettes. More than half of the respondents disagreed that e-cigs are an effective smoking cessation aid. None
(0 %) offered the strongest level of agreement for recommending e-cigs to their clients/patients, but GPs agreed
to a lesser degree a bit more often than tobacco counselors. Almost none had information leaflets for potentially
interested patients. Finally, the majority of our sample also believed that e-cigs will cause renormalization of
smoking and that e-cigs will lead to an uptake of conventional smoking and disagreed with allowing vaping in
enclosed public places.
Conclusions: Health professionals in Flanders perceive the potential health risks of vaping as lower than those of
smoking but do not recommend using e-cigs to their smoking patients.
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Background
Despite all tobacco control efforts, reductions in smoking
prevalence in Belgium—much like in most other countries
in Western Europe—appear to have stalled over the last
decade [1]. Yearly surveillance of smoking among samples
that are representative of the Belgian population (aged
15–75) shows that in the most recent period 2011–2015,
smoking prevalence kept hovering around 25 %. Many
smokers claim to have the intention to quit and many
make actual quit attempts, but the vast majority are un-
successful. Of those who choose to try quitting without
any assistance (by “willpower” alone), no more than 3–5 %
are typically found to be abstinent 6–12 months later [2].
Those smokers who choose medically approved smoking
cessation aids, including quit-smoking medication (such
as Varenicline), nicotine-replacement therapy (NRT), and/
or behavioral counseling, at best double or triple their
chances of long-term success [3]. For example, in the most
recent analysis of the UK National Health Stop Smoking
Services’ long-term outcomes, no more than 8 % of the
clients (most of them having received a combination of
behavioral counseling plus NRT or quit-smoking medica-
tion) showed carbon monoxide (CO)-validated cessation
at 1 year [4].
This failure of traditional tobacco control may in part
be related to the fact that its ultimate objective is the
eradication of any form of tobacco and nicotine use.
This goal may not be attainable, nor even be desirable
for many smokers. Tobacco harm reduction (THR)—en-
couraging the substitution of low-risk alternatives—may
provide a viable alternative for those smokers who can-
not or do not want to cease all tobacco and/or nicotine
consumption [5–7]. Like other low-risk nicotine prod-
ucts such as smokeless tobacco (e.g., Swedish suns),
electronic cigarettes (e-cigs) may represent a useful tool
for THR.
E-cigs completely avoid the combustion of organic ma-
terial (c.q., tobacco), and hence most of the toxic and car-
cinogenic chemicals that are present in cigarette smoke. A
systematic review by Burstyn of current knowledge of the
chemical composition and the toxicological profile of e-
cig aerosols [8] indicates that the deleterious constituents
of tobacco smoke, including carcinogens, are either absent
or, if present, at levels mostly below 1 % of the levels typic-
ally found in cigarette smoke, whereas the main chemicals
predominant in, or unique to, e-cig vapor have not been
associated with any serious risk [9]. Burstyn [8] (p. 12)
thus concluded that “the current state of knowledge about
the chemistry of contaminants in liquids and aerosols as-
sociated with electronic cigarettes indicates that there is
no evidence that vaping produces inhalable exposures to
these contaminants at a level that would prompt measures
to reduce exposure by the standards that are used to en-
sure safety of workplaces.” In the same vein, reviews of the
studies on the clinical safety of (short-term) exposure to
e-cig aerosols come to the conclusion that there is cur-
rently no evidence for (irreversible) harmful effects of
using e-cigs on the respiratory or cardiovascular system;
that the effects of vaping are beyond any reasonable doubt
significantly less harmful than the effects of smoking; and
that e-cigs probably also pose no more than minor health
risks in an absolute sense. However, given the fact that e-
cigs have been widely consumed for less than a decade,
there inevitably remains a degree of uncertainty about the
health effects of long-term e-cig use. [10, 11], see also [9].
For the e-cig to be useful as a THR tool, it is important to
demonstrate not only that it is indeed a low-risk nicotine
delivery product but also that it is accepted by (current)
smokers and that it is effective with respect to smoking re-
duction or cessation. Initial evidence bearing on these ques-
tions is promising. E-cigs seem to gain wide acceptance and
substantial market penetration among smokers, at least in
those countries where e-cigs with nicotine are easily avail-
able. According to the latest Eurobarometer [12], about
10 % of the total EU population aged 15+ (about 43 million
people) are smokers or ex-smokers that use or have
ever tried e-cigs. Of those, 14 % report complete smok-
ing cessation and 21 % report smoking reduction,
whereas 13 % report having quit smoking but started
again. In absolute numbers, these Eurobarometer figures
translate into roughly 6 million quitters, 9 million reducers,
and 5.5 million “temporary quitters” among smokers that
use or ever tried e-cigs. In the most recent ASH data [13],
about 59 % of all smokers in Great Britain ever tried an e-
cig, and 18 % (2.6 million adults) currently use e-cigs
(about 2 out of 5 users are now ex-smokers and 3 out of 5
are current smokers or “dual users”), mainly to reduce the
amount they smoke (dual users) or to remain abstinent
from tobacco smoking (quitters).
There is also evidence that medical professionals and to-
bacco counselors who choose to intervene to aid smoking
cessation can promote e-cigs. This is certainly not trivial:
for example, in a recent survey by Phillips (n = about 20
000) [14] among American vaping enthusiasts (members
of the Consumer Advocates for Smoke-free Alternatives
Association (CASAA)), about 1 out of 5 reported either
“to have become interested in e-cigs in the first place due
to advice of a healthcare provider,” or “that a provider
volunteered a recommendation to try e-cigs, though the
subject was already using them or considering it.” In a ran-
domized controlled trial (RCT) in New Zealand, by Bullen
and colleagues, a comparison was made between the effi-
cacy of e-cigs and nicotine patches for smoking cessation
in smokers wanting to quit [15]. After 6 months, 7 % of
the participants were completely abstinent from tobacco
cigarettes with nicotine e-cigs, 6 % with nicotine patches,
and 4 % with “placebo” (no-nicotine) e-cigs. In a second
RCT in Italy, Caponnetto and colleagues offered smokers
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not intending to quit either nicotine-containing e-cigs or
no-nicotine e-cigs [16]. After 12 months, quit rates were
11 versus 4 %, respectively. It is important to note that
these earlier prospective trials and RCTs used closed sys-
tem e-cigs that are by now obsolete and underperforming
compared with current models. A more recent RCT by
Adriaens, Van Gucht, Declerck, and Baeyens [17] and a
prospective cohort study by Polosa et al. [18] assessed the
efficacy of better performing open system e-cigs in Flemish
and Italian (resp.) smokers without the intention to quit
and observed biologically verified quit rates in 21–36 % of
all participants at 6–8 months after the start of the inter-
vention and a smoking reduction of at least 50 % in an
additional 23–30 % of participants. Finally, in another
study by Polosa and colleagues targeting a somewhat dif-
ferent population of smokers who were naïve about e-cigs
but clearly interested in them, a prospective real-world
study of first-time vape shop visitors in Italy, the 12-
month quit rate was as high as 41 %, whereas an additional
25 % of customers reduced smoking by at least 50 % [19].
In sum, in several clinical trials and a real-world study, the
use of e-cigs has been demonstrated to be associated with
smoking cessation and reduction.
However, many misperceptions of both risks and oppor-
tunities of e-cigs exist both in the general population and
among physicians, and the latter appears to be somewhat
reluctant to recommend using them to their patients. So
far, one study by Kandra, Ranney, Lee, and Goldstein [20]
measured attitudes toward e-cigs among North Carolina
physicians treating adult smokers. About two-thirds of the
physicians who participated correctly believed that e-cigs
lower the risk of cancer when they are used instead of
smoking cigarettes, and a similar number agreed that e-
cigs are a helpful aid for smoking cessation. Nevertheless,
only 35 % actually recommended an e-cig to their smok-
ing patients. In a similar vein, Steinberg, Giovenco, and
Delnevo [21] found that two-thirds of a convenience sam-
ple of US physicians who participated in a web-based sur-
vey on patient-physician communication regarding e-cigs
reported that patients inquire about e-cigs, whereas no
more than 30 % of the physicians reported that they had
recommended e-cigs as a smoking cessation tool. In an-
other study by Pepper, Gilkey, and Brewer, among US
pediatricians and family medicine physicians who provide
primary care to adolescents [22], only 1 out of 4 would
recommend e-cigs to their adolescent patients as a smok-
ing cessation tool. If asked, less than half of these physi-
cians would tell their smoking patients that they believe
that e-cigs are less harmful than cigarettes.
Results from a US National Survey 2012–2013 are in
line with these observations in physicians: Only 51 % of
the general population believed that e-cigs are less harm-
ful than cigarettes [23]; the authors concluded that there
is a strong discrepancy between the scientific evidence
and the perceptions of the general population when it
comes to tobacco harm reduction. The same pattern has
been confirmed in Great Britain, the results of the latest
Action on Smoking and Health survey [24] showing that
only 45 % of the general public believe e-cigs to be less
(30 %) or a lot less (15 %) harmful than cigarettes, whereas
among current smokers, only 12 % believe e-cigs to be a
lot less harmful and 25 % believe e-cigs to be more or
equally harmful than smoking.
In the current study, we compared two groups of health-
care providers in Flanders with regard to their attitudes
and risk perceptions concerning e-cigs, registered tobacco
counselors having obtained a training and being certified
as “tabacologists” and general practitioners (GPs). As a
point of reference, we also report the data obtained in a
convenience sample of members from the general public.1
Apart from measuring general perception of harm from
using e-cigs relative to smoking tobacco cigarettes, we also
gained information on their beliefs concerning cancer,
cardiovascular, and respiratory risks, and concerning the
addictive properties of vaping. We also assessed attitudes
about possible “gateway effects” and “renormalization” of
smoking, their opinion about selling e-cigs to minors, the
use of e-cigs in enclosed public places, and the potential of
e-cigs as a smoking cessation tool.
Methods
Participants
Tobacco counselors and GPs were contacted through
different channels. In 2014, in Flanders, there were 205
registered tobacco counselors who were all invited via
e-mail to participate in our study: more than 25 %
responded (n = 54) to our request. We e-mailed different
associations of GPs to distribute our request (via e-mail)
to their members, because individual e-mail addresses
were not available. We do not know how many of these
associations actually forwarded the invitation to partici-
pate and consequently, how many GPs received our invi-
tation. The response rate in this population was low (n =
22), probably also because of the fact that GPs are over-
burdened by requests to participate in research. In total,
the sample consisted of 76 respondents who completed
the questionnaire: 29 % were GPs and 71 % were people
trained as tobacco counselors (with another health care
profession such as for example psychologists).
Measures
The online questionnaire, made in Qualtrics, started with
some questions assessing background information: age,
gender, smoking status (smoker, ex-smoker, non-smoker),
vaping status (ever tried an e-cig, regular user of e-cig),
profession, number of years in the field, number of pa-
tients (in total and per workday), and estimation of the
prevalence of smokers among their patients. Respondents
Van Gucht and Baeyens Harm Reduction Journal  (2016) 13:22 Page 3 of 8
were also asked for the rate at which they informed their
patients about e-cigs (never, almost never, sometimes,
often) and whether they had information brochures on e-
cigs (yes-no). The questions on the attitudes and percep-
tions about e-cigs were based on those used by Kandra et
al. [20] but extended with others constructed by the
authors (for the literal English translation of all statements
that appeared in the questionnaire, see Table 3). The state-
ments could be rated from 1 (totally disagree), over 2 (ra-
ther disagree) and 3 (rather agree), to 4 (totally agree).
Some were on the safety and the addictive properties of
e-cigs in absolute terms, for example “The electronic
cigarette is harmful to the vaper” and “The electronic
cigarette with nicotine has an addictive effect,” others
compared e-cigs with regular tobacco cigarettes, for ex-
ample “The risk of cardiovascular disease is lower for the
electronic cigarette than for the conventional cigarette.”
Statements about possible “gateway” and “renormalization”
effects, e.g., “I think that the electronic cigarette will lead to
uptake of conventional smoking,” selling to minors “I think
the electronic cigarette should be prohibited to minors
(18 years),” and use in public places “I think the electronic
cigarette can be used in public places where smoking is
prohibited” were also included. Finally, respondents were
also asked about the potential of e-cigs as a smoking cessa-
tion aid, if they would support patients who spontaneously
tell them they want to start using the e-cig in this decision
and if they would recommend e-cigs to their smoking
patients (see also Table 3).
Procedure
In the invitation e-mail, the goal of the study was
stated, namely to gain more insight in the knowledge
and attitudes regarding e-cigs in different populations.
Participants were then referred to the online survey via
a Qualtrics link. The procedure was approved by the
ethical committee of Thomas More University College.
Results
Participants’ characteristics
Respondents averaged 45 years old (range 24–65).
Forty percent of the tobacco counselors and 33 % of
the GPs were male. Their smoking status appears in
Table 1. Three respondents had tried an e-cig, but
none used them regularly.
The respondents had on average more than 17 years ex-
perience in the field, more than 800 patients in total, and
saw about 12 patients on a regular workday (Table 2).
They estimated that 42 % of their patients/clients were
current smokers. Note that tobacco counselors estimated
that among their patients, only half smoke this is because
most tobacco counselors also have another profession
(nurse, psychologist, etc.).
Only two professionals never or seldom asked their
patients/clients about their current smoking status. Al-
most one third asked it sometimes, and two thirds
asked it always. For obvious reasons, tobacco coun-
selors asked this significantly more frequently than GPs,
Ws = 1884, z = −2.701, p < .01. The majority reported that
their patients inform about e-cigs, significantly more so
for tobacco counselors than for GPs, Ws = 551, z = −3.684,
p < .001; a quarter of professionals reported that their pa-
tients do it often, about half sometimes, and the other
quarter almost never to never. Finally, only five profes-
sionals answered affirmatively that they had any informa-
tion brochures on vaping to hand out to their patients.
Perceptions and attitudes on e-cigs
In this section, we take a closer look at the GPs’ and to-
bacco counselors’ perceptions and attitudes on e-cigs.
We refer to Table 3 for the distributions of responses for
each statement.
More than two thirds of the sample studied agreed
(“rather agree” and “totally agree combined) with the
statement that e-cigs are harmful to the vaper, and about
one third agreed that e-cigs are harmful to people in the
vicinity of the vaper. Almost 1 out of 5 of the profes-
sionals disagreed (“rather disagree” and “totally disagree”
combined) that e-cigs are healthier than conventional
cigarettes. About half of the professionals agreed with
the statement that e-cigs are carcinogenic, while more
than 8 out of 10 agreed, however, that the risk of cancer
is lower for e-cigs than for the conventional cigarette.
According to two thirds of our sample, e-cigs increase
cardiovascular risk, but more than 8 out of 10 agreed
with the statement that the risk of cardiovascular disease
is lower for e-cigs than for conventional ones.
With regard to chronic lung disease, almost half of the
professionals agreed that e-cigs increase that risk, but again,
about 8 out of 10 agreed with the statement that the risk of
chronic lung disease is lower for e-cigs than for conven-
tional cigarettes. About half of the sample agreed with the
Table 1 Participants’ smoking status
Smoker (%) Ex-smoker (%) Non-smoker (%)
GPs 5 18 77
Tobacco counselors 0 43 57
Total 1 36 63
Table 2 Participants’ characteristics
GPs Tobacco Total
M M M
Number of years in field 21 16 18
Number of patients in total 1693 263 808
Number of patients/workday 19 9 12
Estimated % of smoker among patients 25 51 42
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statement that nicotine is a very harmful component of e-
cigs. With regard to the addictive properties of e-cigs, 9 out
of 10 agreed that e-cigs with nicotine have an addictive
Table 3 Tobacco counselors and general practitioners’
distributions of responses on the different statements
Totally
disagree
(%)
Rather
disagree
(%)
Rather
agree
(%)
Totally
agree
(%)
The e-cig is harmful to
the vaper
TCs 4 26 63 7
GPs 0 32 55 14
Total 3 28 61 9
The e-cig is harmful to
people in the vicinity
of the vaper
TCs 22 48 24 6
GPs 9 55 27 9
Total 18 50 25 7
The e-cig is healthier
than the conventional
cigarette
TCs 7 11 39 43
GPs 5 9 55 32
Total 7 11 43 40
The e-cig is carcinogenic TCs 11 41 35 13
GPs 18 41 27 14
Total 13 41 33 13
The risk of cancer is
lower for the e-cig
than for the
conventional
cigarette
TCs 2 13 43 43
GPs 5 5 59 32
Total 3 11 47 40
The e-cig increases the
cardiovascular risk
TCs 6 30 44 20
GPs 9 23 55 14
Total 7 28 47 18
The risk of cardiovascular
disease is lower for the
e-cig than for the
conventional cigarette
TCs 7 7 52 33
GPs 5 5 73 18
Total 7 7 58 29
The e-cig increases the
risk of chronic lung
disease
TCs 11 41 41 7
GPs 9 41 36 14
Total 11 41 40 9
The risk of chronic lung
disease is lower for the
e-cig than for the
conventional cigarette
TCs 4 17 44 35
GPs 5 9 73 14
Total 4 15 53 29
Nicotine is a very
harmful component
of the e-cig
TCs 24 30 28 19
GPs 4 50 27 18
Table 3 Tobacco counselors and general practitioners’
distributions of responses on the different statements
(Continued)
Total 18 36 28 18
The e-cig with nicotine
has an addictive effect
TCs 2 7 35 56
GPs 0 14 41 46
Total 1 9 37 53
The e-cig without
nicotine has an
addictive effect
TCs 20 43 32 6
GPs 18 46 32 5
Total 20 43 32 5
I think the e-cig can
be used in public
places where smoking
is prohibited
TCs 70 19 9 2
GPs 36 36 18 9
Total 61 24 12 4
I think the e-cig should
be prohibited to minors
(18 years)
TCs 2 11 20 67
GPs 5 5 27 64
Total 3 9 22 66
I think the e-cig will
cause renormalisation
of smoking
TCs 2 15 50 33
GPs 5 23 46 27
Total 3 17 49 32
I think that the e-cig
will lead to uptake of
conventional smoking
TCs 4 22 52 22
GPs 9 27 46 18
Total 5 24 50 21
The e-cig is an effective
smoking cessation aid
TCs 24 43 32 2
GPs 5 46 50 0
Total 18 43 37 1
I support patients, who
spontaneously tell me
they want to start using
the e-cig, in this decision
TCs 20 39 33 7
GPs 5 27 59 9
Total 16 36 41 8
I recommend the e-cig
to my patients
TCs 57 37 6 0
GPs 32 59 9 0
Total 50 43 7 0
TCs tobacco counselors, GPs general practitioners
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effect, and more than one third agreed that e-cigs without
nicotine have an addictive effect.
More than 8 out of 10 of the respondents disagreed
with allowing the use of e-cigs in enclosed public places
where smoking is prohibited. Almost 9 out of 10 agreed
that e-cigs should be prohibited to minors and 8 out of
10 agreed that e-cigs will cause renormalization of
smoking; moreover, 7 out of 10 believed that e-cigs will
lead to uptake of conventional smoking.
About two thirds of the respondents disagreed with the
statement that e-cigs are an effective smoking cessation
aid, with a trend for tobacco counselors to answer more
negatively than GPs (24 vs. 5 % totally disagree, see
Table 3). In order to test the reliability of this interesting
difference between the two populations in the endorse-
ment of the different response categories for this item, we
used the Wilcoxon rank-sum test, Ws = 1932, z = −1.813,
p = .07.
About half of the respondents support patients who
spontaneously tell them that they want to start using e-cigs;
noteworthy, GPs were significantly more supportive than
tobacco counselors (68 vs. 41 %), Ws = 1901.5, z = −2.163,
p < .05. When professionals were asked if they would rec-
ommend e-cigs to their smoking patients, none totally
agreed and less than 1 out of 10 rather agreed, while 4 out
of 10 rather disagreed and 5 out of 10 totally disagreed. In
line with the above, tobacco counselors answered signifi-
cantly more negatively than GPs (57 vs. 32 % totally dis-
agree with recommendation to the patients, see Table 3),
Ws = 1926, z = −1.916, p = .05.1
Discussion
In this survey of health professionals’ beliefs about e-
cigs, striking similarities with earlier results obtained in
the UK and the USA (also see [25]) were observed.
There is currently no identified serious health risk asso-
ciated with vaping, and the likelihood of long-term e-cig
use being implicated in the development of chronic or
fatal disease is estimated to be low and in the range of
1/20th to 1/100th of that of smoking [8–11]. About 3 in
4 of our studied sample believed that e-cigs are harmful
to vapers, whereas around half to two thirds of the sam-
ple believed that e-cigs are carcinogenic and increase the
cardiovascular risk and the risk of chronic lung disease.
Also, a substantial minority incorrectly believed these
risks to be no less than those resulting from regular
smoking: a majority of the professionals rightfully be-
lieved that vaping involves smaller health risks than
smoking, but 10–20 % of them disagreed that e-cigs are
healthier and represent less risk for the main serious
smoking-related diseases than conventional cigarettes.
Whereas the interpretation of participants’ answers on
these items asking about the perceived relative risks of
e-cigs (compared to smoking) is rather straightforward,
the meaning of the answers on the items asking for the
perceived harmful effects of e-cigs in absolute terms may
be more problematic, especially considering the nature of
the response alternatives provided (from totally disagree
to totally agree). Namely, several different interpretations
of the latter questions and/or responses alternatives may
have been possible. The authors’ best guess is that these
questions were interpreted and mentally rewritten as
meaning “is there a substantial risk for (harm/cancer/car-
diovascular disease/lung disease)” or “is there a risk large
enough to be detected that has been documented,” rather
than “is there any non-zero risk, however small.” Accord-
ingly, we interpret agreement with these absolute risk
statements as (hesitant or full) endorsement of substantial
risk claims, rather than as the rejection of non-zero risk
claims. Alternatively, the less emphatic “rather” (dis)agree
response alternatives may have been selected to express
quantification (e.g., “rather agree with risk x” meaning
“yes, some risk, but not a high risk of x”) rather than de-
grees of certainty (“rather agree with risk x” = “yes, sub-
stantial risk of x, but I am not completely confident about
this”). Consequently, it is probably safer to interpret these
findings cautiously, as reflecting general (negative) atti-
tudes toward the questioned health risks rather than as
precise risk estimates.
Almost half of the professionals agreed with the state-
ment that nicotine is a very harmful component of e-cigs.
This is a serious misconception in and of itself but probably
also represents a major stumbling block for any successful
implementation of a THR strategy [26]. Epidemiological
data on the long-term use of a related highly-reduced-risk
smokeless nicotine product, Swedish snus, reassuringly
confirms that any increase in cardiovascular disease or can-
cer from snus use is speculative, and if it exists is probably
about 1 % of that from smoking [27–29]. Likewise, research
on classical NRT (patches, inhalers, chewing gum) shows
that long-term use of nicotine per se does not reliably in-
crease serious cardiovascular risk [30]. In sum, at least for
non-pregnant adults and at the doses typically consumed
by vapers, there is little that would justify the professionals’
apparent strong belief in the harmfulness of nicotine as
consumed by means of e-cigs [5, 31].
Being contacted in their capacity as health professionals,
participants most likely answered the item about the ef-
fectiveness of e-cigs as referring to the question whether
they believed e-cigs to be effective as smoking cessation
aids when used in the context of a clinical intervention.
More than half of our sample disagreed so, although re-
cent randomized controlled trials, and prospective inter-
ventional clinical trials demonstrate that e-cigs can indeed
help some people to quit smoking or to substantially de-
crease their cigarette consumption [17, 18]. In line with
this disbelief in the efficacy of e-cigs as quit-smoking aids,
in our sample, none (0 %) of the professionals totally
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agreed recommending e-cigs to their clients/patients, and
almost none had information leaflets for potentially inter-
ested patients.
Less than 1 out of 10 smokers who want to quit turn
for help to a professional; these are probably smokers
who have tried many aids and made lots of unsuccessful
quit attempts already. If not given the right advice when
asking about e-cigs, these “die-hard” smokers, for whom
THR might be the best long-term strategy, are denied
access to a potentially life-saving alternative. Moreover,
health professionals trained as tobacco counselors were
even more reluctant about recommending e-cigs than
GPs. At the time of the survey, information on the safety
or on the effectiveness of e-cigs was completely absent in
the training of tobacco counselors. This may, in addition
to the almost exclusively negative media communication
on e-cigs in Flanders, have contributed to participants’
dismissal of e-cigs as a (clinical) quit-smoking aid.
Even though about two thirds of all participants (cor-
rectly, see for example [32, 33]) disagreed that there is a
risk of “second-hand exposure” for people in the vicinity
of the vaper, results also showed that more than 80 % dis-
agreed with allowing the use of e-cigs in enclosed public
places where smoking is prohibited. The majority of our
sample also believed that e-cigs will cause renormalization
of smoking and that e-cigs will lead to an uptake of con-
ventional smoking, comparable to recent findings from
Tan et al. [25] showing that more than half of their nation-
ally representative sample of US adults agreed that e-cigs
tempt non-smoking youth to start smoking regular ciga-
rettes and that e-cigs make smoking more acceptable to
youth. Available data do not allow to validly support but
neither to convincingly exclude the existence of a “gate-
way-effect” (that is, non-smokers starting to smoke as a
consequence of first having started to vape) [11, 34, 35],
nor do they suggest an increase in smoking prevalence in
populations where vaping prevalence has increased re-
cently, e.g., [36–38] for recent data on the USA and UK
smoking and vaping prevalence].
Conclusions
Our results suggest that few smokers consulting health
professionals in Flanders will get medical advice to switch
to e-cigs. The virtual absence in the education of GPs as
well as in the training of tobacco counselors of up-to-date
and balanced summaries of current scientific knowledge
on THR in general and on e-cigs in particular, may—at
least partially—explain this observation.
Endnotes
1In order to put some of these data into perspective, the
results obtained from a convenience sample of members
of the general public (n = 82; male/female ratio = 1:2; M
age = 26; 23 % smokers; 1 % vapers; 15 % tried e-cigs;
recruited via social media (Facebook) on which a call was
launched to participate in a web-based survey “to gain
more insight into the knowledge and attitudes regarding
e-cigs in different populations”) who filled out the same
online questionnaire (excluding the items specific to the
professional-client interaction) can be summarized as fol-
lows. Just like the professionals, the majority (7 in 10) of
non-professionals endorsed the statements that e-cigs are
harmful to the vaper, whereas 4 out of 10 believed that e-
cigs cause harm to people in the vicinity of the vaper;
moreover, about 1 in 3 disagreed that e-cigs are healthier
than tobacco cigarettes. In the same vein, the majority of
the non-professionals also agreed with the statements
expressing cancer, cardiovascular, and lung risk of using e-
cigs (6 to 7 out of 10), while at the same time, a majority
(about 7 out of 10) believed the comparative risks to be
lower than those of smoking. If anything, both absolute
and relative health risk perceptions were more negative in
the non-professional convenience sample than in the pro-
fessionals. About 3 out of 4 agreed that nicotine is a very
harmful component of e-cigs, and similar to the profes-
sionals almost 9 out of 10 agreed upon the addictive effect
of nicotine-containing e-cigs (1 out of 3 for e-cigs without
nicotine). Finally, the majority of the non-professionals
also supported a public vaping ban (7 out of 10) and pro-
hibition of sales to minors (8 in 10) and believed that e-cig
will lead to renormalization (5 out of 10) and uptake of
conventional smoking (7 out of 10) but disagreed that
e-cigs are an effective smoking cessation aid (4 in 10).
If anything, beliefs in smoking-enhancing consequences
(renormalization and uptake smoking) and endorse-
ment of restrictive policies on the use of e-cigs (public
vaping ban and prohibition of sales to minors) were some-
what less pronounced in the non-professional sample than
in the professionals.
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